Pharmatest offers clinically predictive preclinical efficacy services for the pharmaceutical industry for testing their drug candidates in the fields of oncology and skeletal diseases. The company has already a wide customer base in the U.S. With the new sales office and increased U.S. sales and marketing efforts, Pharmatest expects to rapidly grow the number of U.S. customers and sales figures.
“I am very excited for the opportunity to work for Pharmatest,” said Cambridge new-hire Andrew Heiniluoma, Pharmatest U.S. Sales Representative. “Cambridge is a perfect site for a U.S. sales office, and the Boston area is unique in the U.S. in terms of the presence of the pharma industry, providing an outstanding opportunity for attracting new customers for Pharmatest.”
“The U.S. has the biggest market potential for our services, and we now have a clear strategy to focus on increasing our U.S. market share,” said Jussi Halleen, CEO of Pharmatest. “We are very happy to have Andy on board in Cambridge, which allows us to get closer to our customers. I am convinced that this will boost our U.S. revenues in the coming years.”
“Investing in education, innovation and infrastructure is a winning growth strategy for Massachusetts and is the reason we lead the world in life sciences,” said Governor Deval Patrick. “We welcome Pharmatest to the Massachusetts biotech supercluster and look forward to the jobs and economic opportunities they bring.”
Through the Massachusetts Life Sciences Center, Massachusetts is investing $1 billion over 10 years in the growth of the state’s life sciences supercluster. These investments are being made under the Massachusetts Life Sciences Initiative, proposed by Governor Patrick in 2007, and passed by the State Legislature and signed into law by Governor Patrick in 2008.
“We are excited to welcome Pharmatest to the fast-growing Massachusetts life sciences supercluster,” said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center. “Pharmatest is part of a growing community of international life sciences companies that have chosen Massachusetts as the best place to expand and do business. We are confident that Pharmatest, as a contract research organization, will find in Massachusetts the partners and client base they need to be successful.”
Pharmatest is among a growing group of international companies that have recently picked Massachusetts as the place to expand their business in the U.S.
“I am pleased to learn of Pharmatest’s new office in Cambridge,” said Senator Anthony Petruccelli. “Kendall Square and the City of Cambridge continue to be the most attractive environment for our life sciences industry.”
“I'm thrilled to see another global company creating jobs in Cambridge,” said Representative Timothy Toomey. “Pharmatest's solid performance record is clear, and I welcome them to our community.”
“I join the Governor in welcoming Pharmatest to Massachusetts,” said Tom Gradel, Manager of Business Development and Protocol Officer at the Massachusetts Office of International Trade & Investment. “Pharmatest will join a broad and deep ecosystem in the global hub of life sciences.”
“Massachusetts has become the destination for the world’s most innovative companies across the entire life sciences spectrum,” said Robert K. Coughlin, President & CEO of MassBio, a 600+ member life sciences trade association. “We are thrilled to welcome Pharmatest and know they will play a very important role in our world-class life sciences ecosystem.”
Pharmatest’s new U.S. office is based at:
Pharmatest Services Ltd
Cambridge Innovation Center
Cambridge, MA 02142
USA
Media Contacts:
Andrew Heiniluoma
U.S. Sales Representative
Pharmatest Services Ltd
andrew.heiniluoma@pharmatest.com
+1 978 340 1028
Angus G. McQuilken
Vice President for Communications & Marketing
Massachusetts Life Sciences Center
amcquilken@masslifesciences.com
+1 617 921 7749
About Pharmatest Services Ltd
Pharmatest's headquarters and preclinical research unit are located in Turku, Finland, where the company operates in modern facilities, including fully-equipped research laboratories and barrier-type animal facilities. In addition to its newest office in Cambridge, Massachusetts, USA, Pharmatest has a sales office in Guangzhou, China.
Pharmatest can help establish the proof-of-efficacy of cancer drug candidates with clinically predictive cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Our models of skeletal diseases include clinically predictive bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.
For more information, visit www.pharmatest.com.
About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a 10-year, $1-billion initiative that was signed into law in June of 2008. The MLSC’s mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties among sectors of the Massachusetts life sciences community. For more information, visit www.masslifesciences.com.
